210 related articles for article (PubMed ID: 26159519)
1. Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes.
Khan FH; Pandian V; Ramraj S; Natarajan M; Aravindan S; Herman TS; Aravindan N
BMC Cancer; 2015 Jul; 15():514. PubMed ID: 26159519
[TBL] [Abstract][Full Text] [Related]
2. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
3. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes.
Khan FH; Pandian V; Ramraj SK; Aravindan S; Natarajan M; Azadi S; Herman TS; Aravindan N
Oncotarget; 2015 Nov; 6(34):36522-34. PubMed ID: 26375249
[TBL] [Abstract][Full Text] [Related]
4. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Khan FH; Pandian V; Ramraj S; Aravindan S; Herman TS; Aravindan N
BMC Genomics; 2015 Jul; 16(1):501. PubMed ID: 26148557
[TBL] [Abstract][Full Text] [Related]
5. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma.
Vettenranta K; Aalto Y; Wikström S; Knuutila S; Saarinen-Pihkala U
Cancer Genet Cytogenet; 2001 Mar; 125(2):125-30. PubMed ID: 11369055
[TBL] [Abstract][Full Text] [Related]
7. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
8. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution.
Somasundaram DB; Subramanian K; Aravindan S; Yu Z; Natarajan M; Herman T; Aravindan N
Sci Rep; 2019 Aug; 9(1):11766. PubMed ID: 31409909
[TBL] [Abstract][Full Text] [Related]
9. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of segmental alterations determines progression in neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Ribeiro A; Klijanienko J; Couturier J; Pierron G; Mosseri V; Valent A; Auger N; Plantaz D; Rubie H; Valteau-Couanet D; Bourdeaut F; Combaret V; Bergeron C; Michon J; Delattre O
J Clin Oncol; 2010 Jul; 28(19):3122-30. PubMed ID: 20516441
[TBL] [Abstract][Full Text] [Related]
12. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
[TBL] [Abstract][Full Text] [Related]
15. TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.
Middelbeek J; Visser D; Henneman L; Kamermans A; Kuipers AJ; Hoogerbrugge PM; Jalink K; van Leeuwen FN
Oncotarget; 2015 Apr; 6(11):8760-76. PubMed ID: 25797249
[TBL] [Abstract][Full Text] [Related]
16. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.
Morales La Madrid A; Nall MB; Ouyang K; Minor A; Raca G; Kent P; Miller I; Schleiermacher G; Janoueix-Lerosey I; Cohn SL
Pediatr Blood Cancer; 2013 Feb; 60(2):332-5. PubMed ID: 22997192
[TBL] [Abstract][Full Text] [Related]
17. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
Fernández-Blanco B; Berbegall AP; Martin-Vañó S; Castel V; Navarro S; Noguera R
Neoplasia; 2021 Jan; 23(1):12-20. PubMed ID: 33190090
[TBL] [Abstract][Full Text] [Related]
18. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
[TBL] [Abstract][Full Text] [Related]
20. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
